Eutálio Luiz Mariani Pimenta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eutálio Luiz Mariani Pimenta has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Francisco José Teixeira Neto
Department of Veterinary Surgery and Animal Reproduction, Faculdade de Medicina Veterinária e Zootecnia, Universidade Estadual Paulista (UNESP), Botucatu, Brazil
2 shared publications - Natália Fagundes
Universidade Federal de Minas Gerais
2 shared publications - Suzane Lilian Beier
Department of Clinical and Veterinary Surgery, Veterinary School, Universidade Federal de Minas Gerais, UFMG, Belo Horizonte 31270-901, MG, Brazil
2 shared publications Adriana V. Klein
Faculdade de Medicina Veterinária e Zootecnia, Universidade Estadual Paulista (UNESP), Botucatu, SP, Brazil
1 shared publication- Andressa Karollini da Silva
Universidade Federal de Minas Gerais
1 shared publication C. B. Detoni
Faculty of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
1 shared publication
Latest Publications
- Open Access
- 4 September 2026
- Published by Elsevier in Veterinary Anaesthesia and Analgesia
- Vol. 53 (6)
Recovery quality and antinociceptive effects following rectus abdominis sheath block in dorsally recumbent horses: an experimental study
- 4 September 2026
- Published by Elsevier in Veterinary Anaesthesia and Analgesia
- Vol. 53 (6)
Open AccessRecovery quality and antinociceptive effects following rectus abdominis sheath block in dorsally recumbent horses: an experimental study
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Ciência Rural
- Vol. 54 (4) , e20220259
Clinical and Doppler echocardiographic evaluation of rabbits sedated with dexmedetomidine in combination with midazolam and morphine
The objective of the present study was to evaluate clinical, cardiorespiratory, and Doppler echocardiographic changes in rabbits sedated with midazolam and morphine combined with or without dexmedetomidine. This study was a blinded, randomized, controlled experiment that included 16 adult male New Zealand rabbits weighing 3.1 ± 0.3 kg. The animals were sedated using one of the following protocols: 1 mg/kg midazolam and 2 mg/kg morphine (MIDA, n = 8), or 25 mg/kg dexmedetomidine, 2 mg/kg morphine and 1 mg/kg midazolam (DEX, n = 8). Sedation latency, duration of the sedation and recovery period, sedation scores, heart rate (HR), respiratory rate (f), peripheral oxygen saturation (SpO2), systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), and recta temperature were recorded, and Doppler echocardiography was performed. Latency periods were 7.3±1.6 min in the DEX group and 10.9 ± 5.0 min in the MIDA group (P = 0.112). Sedation duration was 122.4±14 min in the DEX group and 71.2 ± 32 min in the MIDA group (P = 0.005), whereas recovery time was 35.7±17.7 min in the DEX group and 32.5 ± 25.3 min in the MIDA group (P = 0.743). The sedation scores for the DEX group were significantly higher than those for the MIDA group throughout the monitoring period. Reductions in HR, SAP, MAP, and DAP values were observed in both groups relative to baseline values, and were significantly lower in the DEX group compared to the MIDA group. Minimal Doppler echocardiographic changes were observed. Dexmedetomidine used in combination with midazolam and morphine incremented the quality and duration of sedation in rabbits. Both protocols elicited cardiorespiratory changes that were well-tolerated, with minimal changes in myocardial function.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Ciência Rural
- Vol. 54 (4) , e20220259
Open AccessClinical and Doppler echocardiographic evaluation of rabbits sedated with dexmedetomidine in combination with midazolam and morphine
The objective of the present study was to evaluate clinical, cardiorespiratory, and Doppler echocardiographic changes in rabbits sedated with midazolam and morphine combined with or without dexmedetomidine. This study was a blinded, randomized, controlled experiment that included 16 adult male New Zealand rabbits weighing 3.1 ± 0.3 kg. The animals were sedated using one of the following protocols: 1 mg/kg midazolam and 2 mg/kg morphine (MIDA, n = 8), or 25 mg/kg dexmedetomidine, 2 mg/kg morphine and 1 mg/kg midazolam (DEX, n = 8). Sedation latency, duration of the sedation and recovery period, sedation scores, heart rate (HR), respiratory rate (f), peripheral oxygen saturation (SpO2), systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), and recta temperature were recorded, and Doppler echocardiography was performed. Latency periods were 7.3±1.6 min in the DEX group and 10.9 ± 5.0 min in the MIDA group (P = 0.112). Sedation duration was 122.4±14 min in the DEX group and 71.2 ± 32 min in the MIDA group (P = 0.005), whereas recovery time was 35.7±17.7 min in the DEX group and 32.5 ± 25.3 min in the MIDA group (P = 0.743). The sedation scores for the DEX group were significantly higher than those for the MIDA group throughout the monitoring period. Reductions in HR, SAP, MAP, and DAP values were observed in both groups relative to baseline values, and were significantly lower in the DEX group compared to the MIDA group. Minimal Doppler echocardiographic changes were observed. Dexmedetomidine used in combination with midazolam and morphine incremented the quality and duration of sedation in rabbits. Both protocols elicited cardiorespiratory changes that were well-tolerated, with minimal changes in myocardial function.
- Open Access
- 14 February 2023
- Published by Research, Society and Development in Research, Society and Development
- Vol. 12 (3)
Efeitos sedativos e cardiorrespiratórios da detomidina associada ou não ao diazepam em equinos submetidos ao exame odontológico
A sedação para o exame odontológico, em estação, nos equinos é essencial para facilitar o manejo e garantir um exame de excelência. O presente estudo objetivou avaliar se o diazepam associado à detomidina potencializaria a sedação do agonista α2 (detomidina), principalmente pela redução do movimento da língua e mastigação sem excessiva desestabilização. Foram examinados 12 equinos adultos de diferentes idades, raças e sexos submetidos a correção dos arcos dentários e distribuídos aleatoriamente entre dois tratamentos: detomidina (20 µg.kg-1, IV) e diazepam (20 µg.kg-1, IV) (DD; n=6) ou detomidina (20 µg.kg-1, IV) e solução salina de NaCl 0,9% (DS; n=6). Foram avaliados o relaxamento e a exposição da língua, frequência cardíaca, intervalo PR, frequência respiratória, pressão arterial sistólica, temperatura retal, bloqueios atrioventriculares de segundo grau, grau de ataxia, movimento da cabeça, em nove momentos. E a distância da cabeça ao solo (HHAG) foram avaliadas em três momentos. Sempre que houve necessidade de aumentar a sedação, foi administrado um bolus de detomidina adicional (5µg.kg-1, IV). Todos os tratamentos proporcionaram sedação e relaxamento muscular. Foram observadas diferenças entre os momentos para o relaxamento da língua (língua VAS mm) e isto foi melhor observado em T7 para o tratamento DD e T5 para o tratamento DS e manteve-se significativamente inferior à linha de base durante todo o tempo avaliado. O presente estudo sugere que a detomidina forneceu sedação adequada em cavalos submetidos ao exame odontológico mas não há necessidade de utilizar o diazepam da forma proposta porque não foi encontrada qualquer diferença entre tratamentos para qualquer variável estudada. A adição de diazepam não melhorou a sedação e nem diminuiu o movimento da língua.
- 14 February 2023
- Published by Research, Society and Development in Research, Society and Development
- Vol. 12 (3)
Open AccessEfeitos sedativos e cardiorrespiratórios da detomidina associada ou não ao diazepam em equinos submetidos ao exame odontológico
A sedação para o exame odontológico, em estação, nos equinos é essencial para facilitar o manejo e garantir um exame de excelência. O presente estudo objetivou avaliar se o diazepam associado à detomidina potencializaria a sedação do agonista α2 (detomidina), principalmente pela redução do movimento da língua e mastigação sem excessiva desestabilização. Foram examinados 12 equinos adultos de diferentes idades, raças e sexos submetidos a correção dos arcos dentários e distribuídos aleatoriamente entre dois tratamentos: detomidina (20 µg.kg-1, IV) e diazepam (20 µg.kg-1, IV) (DD; n=6) ou detomidina (20 µg.kg-1, IV) e solução salina de NaCl 0,9% (DS; n=6). Foram avaliados o relaxamento e a exposição da língua, frequência cardíaca, intervalo PR, frequência respiratória, pressão arterial sistólica, temperatura retal, bloqueios atrioventriculares de segundo grau, grau de ataxia, movimento da cabeça, em nove momentos. E a distância da cabeça ao solo (HHAG) foram avaliadas em três momentos. Sempre que houve necessidade de aumentar a sedação, foi administrado um bolus de detomidina adicional (5µg.kg-1, IV). Todos os tratamentos proporcionaram sedação e relaxamento muscular. Foram observadas diferenças entre os momentos para o relaxamento da língua (língua VAS mm) e isto foi melhor observado em T7 para o tratamento DD e T5 para o tratamento DS e manteve-se significativamente inferior à linha de base durante todo o tempo avaliado. O presente estudo sugere que a detomidina forneceu sedação adequada em cavalos submetidos ao exame odontológico mas não há necessidade de utilizar o diazepam da forma proposta porque não foi encontrada qualquer diferença entre tratamentos para qualquer variável estudada. A adição de diazepam não melhorou a sedação e nem diminuiu o movimento da língua.
- 10 March 2020
- Published by Wiley in Journal of Medical Primatology
- Vol. 49 (4) , 179-187
Comparison of midazolam and butorphanol combined with ketamine or dexmedetomidine for chemical restraint in howler monkeys (Alouatta guariba clamitans) for vasectomy
Background: This study evaluated and compared cardiorespiratory and blood gas parameters, as well as sedation, analgesia and recovery of two protocols: ketamine (10 mg/kg) or dexmedetomidine (10 μg/kg), with midazolam (0.5 mg/kg) and butorphanol (0.3 mg/kg), IM (KBM and DBM, respectively) in brown howler monkeys (Alouatta guariba clamitans).Material and methods: Twelve brown howler monkeys were selected in two groups and evaluated for cardiorespiratory parameters and sedation, from 5‐30 minutes after latency. Blood gas and arterial lactate were taken at 5 and 30 minutes. In the end, time and quality of recovery were evaluated.Results: The HR in DBM group was significantly lower at all times. The sedation score was higher in DBM. Recovery in DBM was faster. All animals had moderate hypoxaemia.Conclusion: Both protocols produce satisfactory anaesthesia and analgesia, but DBM provides deeper sedation with faster recovery. Oxygen supplementation is recommended in both due to hypoxaemia.
- 10 March 2020
- Published by Wiley in Journal of Medical Primatology
- Vol. 49 (4) , 179-187
Comparison of midazolam and butorphanol combined with ketamine or dexmedetomidine for chemical restraint in howler monkeys (Alouatta guariba clamitans) for vasectomy
Background: This study evaluated and compared cardiorespiratory and blood gas parameters, as well as sedation, analgesia and recovery of two protocols: ketamine (10 mg/kg) or dexmedetomidine (10 μg/kg), with midazolam (0.5 mg/kg) and butorphanol (0.3 mg/kg), IM (KBM and DBM, respectively) in brown howler monkeys (Alouatta guariba clamitans).Material and methods: Twelve brown howler monkeys were selected in two groups and evaluated for cardiorespiratory parameters and sedation, from 5‐30 minutes after latency. Blood gas and arterial lactate were taken at 5 and 30 minutes. In the end, time and quality of recovery were evaluated.Results: The HR in DBM group was significantly lower at all times. The sedation score was higher in DBM. Recovery in DBM was faster. All animals had moderate hypoxaemia.Conclusion: Both protocols produce satisfactory anaesthesia and analgesia, but DBM provides deeper sedation with faster recovery. Oxygen supplementation is recommended in both due to hypoxaemia.
- Open Access
- 1 October 2017
- Published by FapUNIFESP (SciELO) in Arquivo Brasileiro de Medicina Veterinária e Zootecnia
- Vol. 69 (5) , 1251-1258
Cartogenina associada à microperfuração do osso subcondral na reparação da cartilagem articular em equinos
RESUMO A reconstituição da cartilagem articular danificada por doenças de desenvolvimento, trauma e osteoartrite tem sido um grande desafio na veterinária. O objetivo do presente estudo foi avaliar o uso da cartogenina, uma molécula capaz de induzir diferenciação de células mesenquimais em condrócitos, associado ou não à técnica de microfratura na reparação de defeitos condrais induzidos na tróclea femoral de equinos. Foram utilizados seis equinos pesando em média (±DP) 342±1,58kg, com idade de 7,2±1,30 anos e escore corporal de 7,1±0,75, os quais foram submetidos à videoartroscopia para indução da lesão condral de 1cm2 na tróclea lateral do fêmur e à realização da técnica de microperfuração do osso subcondral de ambos os joelhos. Foram realizadas quatro aplicações semanais com 20µM de cartogenina intra-articular em um dos joelhos (grupo tratado) e solução de ringer com lactato na articulação contralateral (grupo controle). Os animais foram submetidos a avaliações física, radiográfica, ultrassonográfica, por um período de 60 dias. Não houve qualquer diferença estatística entre as articulações tratadas e as controle. A terapia com cartogenina, segundo protocolo utilizado, não produziu melhora clínica em lesões osteocondrais induzidas e tratadas com microperfurações na tróclea lateral do fêmur em equinos.
- 1 October 2017
- Published by FapUNIFESP (SciELO) in Arquivo Brasileiro de Medicina Veterinária e Zootecnia
- Vol. 69 (5) , 1251-1258
Open AccessCartogenina associada à microperfuração do osso subcondral na reparação da cartilagem articular em equinos
RESUMO A reconstituição da cartilagem articular danificada por doenças de desenvolvimento, trauma e osteoartrite tem sido um grande desafio na veterinária. O objetivo do presente estudo foi avaliar o uso da cartogenina, uma molécula capaz de induzir diferenciação de células mesenquimais em condrócitos, associado ou não à técnica de microfratura na reparação de defeitos condrais induzidos na tróclea femoral de equinos. Foram utilizados seis equinos pesando em média (±DP) 342±1,58kg, com idade de 7,2±1,30 anos e escore corporal de 7,1±0,75, os quais foram submetidos à videoartroscopia para indução da lesão condral de 1cm2 na tróclea lateral do fêmur e à realização da técnica de microperfuração do osso subcondral de ambos os joelhos. Foram realizadas quatro aplicações semanais com 20µM de cartogenina intra-articular em um dos joelhos (grupo tratado) e solução de ringer com lactato na articulação contralateral (grupo controle). Os animais foram submetidos a avaliações física, radiográfica, ultrassonográfica, por um período de 60 dias. Não houve qualquer diferença estatística entre as articulações tratadas e as controle. A terapia com cartogenina, segundo protocolo utilizado, não produziu melhora clínica em lesões osteocondrais induzidas e tratadas com microperfurações na tróclea lateral do fêmur em equinos.
- 16 January 2017
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 40 (4) , 398-405
Pharmacokinetics and pharmacodynamics of the injectable formulation of methadone hydrochloride and methadone in lipid nanocarriers administered orally to horses
We investigated the thermal, electrical and mechanical antinociceptive and physiological effects (heart rate, respiratory rate, arterial blood pressure, head height and abdominal auscultation score), and pharmacokinetics, of 0.5 mg/kg of the injectable formulation (ORAL) or nanoparticulated methadone (NANO) given orally, in six adult mares, using a crossover, blind and prospective design. Repeated‐measure models were used to compare parametric data between and within treatments, followed by Tukey's test. Nonparametric data were analysed with Wilcoxon signed‐rank, adjusted by Bonferroni tests. Blood samples were also collected up to 6 h after dosing for plasma drug quantification by LC‐MS/MS. Methadone pharmacokinetic parameters were determined by noncompartmental and compartmental approaches. There were no differences in pharmacodynamic parameters. No statistical differences were observed in the pharmacokinetic parameters from noncompartmental analysis for both groups, except a significant decrease in peak plasma concentration, increase in apparent volume of distribution per fraction absorbed (Vdss/F) and increased mean residence time (MRT) for NANO. One‐compartment open model with first order elimination best described the pharmacokinetic profiles for both groups. Neither ORAL nor NANO administered orally to horses produced antinociception. The nanoencapsulated formulation of methadone given orally to horses did not improve methadone pharmacokinetic parameters or increased systemic body exposure to methadone.
- 16 January 2017
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 40 (4) , 398-405
Pharmacokinetics and pharmacodynamics of the injectable formulation of methadone hydrochloride and methadone in lipid nanocarriers administered orally to horses
We investigated the thermal, electrical and mechanical antinociceptive and physiological effects (heart rate, respiratory rate, arterial blood pressure, head height and abdominal auscultation score), and pharmacokinetics, of 0.5 mg/kg of the injectable formulation (ORAL) or nanoparticulated methadone (NANO) given orally, in six adult mares, using a crossover, blind and prospective design. Repeated‐measure models were used to compare parametric data between and within treatments, followed by Tukey's test. Nonparametric data were analysed with Wilcoxon signed‐rank, adjusted by Bonferroni tests. Blood samples were also collected up to 6 h after dosing for plasma drug quantification by LC‐MS/MS. Methadone pharmacokinetic parameters were determined by noncompartmental and compartmental approaches. There were no differences in pharmacodynamic parameters. No statistical differences were observed in the pharmacokinetic parameters from noncompartmental analysis for both groups, except a significant decrease in peak plasma concentration, increase in apparent volume of distribution per fraction absorbed (Vdss/F) and increased mean residence time (MRT) for NANO. One‐compartment open model with first order elimination best described the pharmacokinetic profiles for both groups. Neither ORAL nor NANO administered orally to horses produced antinociception. The nanoencapsulated formulation of methadone given orally to horses did not improve methadone pharmacokinetic parameters or increased systemic body exposure to methadone.
- 14 September 2010
- Published by Wiley in Equine Veterinary Journal
- Vol. 43 (3) , 332-340
Comparative study between atropine and hyoscine‐N‐butylbromide for reversal of detomidine induced bradycardia in horses
Summary: Reasons for performing study: Bradycardia may be implicated as a cause of cardiovascular instability during anaesthesia. Hypothesis: Hyoscine would induce positive chronotropism of shorter duration than atropine, without adversely impairing intestinal motility in detomidine sedated horses. Methods: Ten minutes after detomidine (0.02 mg/kg bwt, i.v.), physiological saline (control), atropine (0.02 mg/kg bwt) or hyoscine (0.2 mg/kg bwt) were randomly administered i.v. to 6 horses, allowing one week intervals between treatments. Investigators blinded to the treatments monitored cardiopulmonary data and intestinal auscultation for 90 min and 24 h after detomidine, respectively. Gastrointestinal transit was assessed for 96 h via chromium detection in dry faeces. Results: Detomidine significantly decreased heart rate (HR) and cardiac index (CI) from baseline for 30 and 60 min, respectively (control). Mean ± s.d. HR increased significantly 5 min after atropine (79 ± 5 beats/min) and hyoscine (75 ± 8 beats/min). After this time, HR was significantly higher after atropine in comparison to other treatments, while hyoscine resulted in intermediate values (lower than atropine but higher than controls). Hyoscine and atropine resulted in significantly higher CI than controls for 5 and 20 min, respectively; but this effect coincided with significant hypertension (mean arterial pressures >180 mmHg). Auscultation scores decreased from baseline in all treatments. Time to return to auscultation scores ≥12 (medians) did not differ between hyoscine (4 h) and controls (4 h) but atropine resulted in significantly longer time (10 h). Atropine induced colic in one horse. Gastrointestinal transit times did not differ between treatments. Conclusion: Hyoscine is a shorter acting positive chronotropic agent than atropine, but does not potentiate the impairment in intestinal motility induced by detomidine. Because of severe hypertension, routine use of anticholinergics combined with detomidine is not recommended. Potencial relevance: Hyoscine may represent an alternative to atropine for treating bradycardia.
- 14 September 2010
- Published by Wiley in Equine Veterinary Journal
- Vol. 43 (3) , 332-340
Comparative study between atropine and hyoscine‐N‐butylbromide for reversal of detomidine induced bradycardia in horses
Summary: Reasons for performing study: Bradycardia may be implicated as a cause of cardiovascular instability during anaesthesia. Hypothesis: Hyoscine would induce positive chronotropism of shorter duration than atropine, without adversely impairing intestinal motility in detomidine sedated horses. Methods: Ten minutes after detomidine (0.02 mg/kg bwt, i.v.), physiological saline (control), atropine (0.02 mg/kg bwt) or hyoscine (0.2 mg/kg bwt) were randomly administered i.v. to 6 horses, allowing one week intervals between treatments. Investigators blinded to the treatments monitored cardiopulmonary data and intestinal auscultation for 90 min and 24 h after detomidine, respectively. Gastrointestinal transit was assessed for 96 h via chromium detection in dry faeces. Results: Detomidine significantly decreased heart rate (HR) and cardiac index (CI) from baseline for 30 and 60 min, respectively (control). Mean ± s.d. HR increased significantly 5 min after atropine (79 ± 5 beats/min) and hyoscine (75 ± 8 beats/min). After this time, HR was significantly higher after atropine in comparison to other treatments, while hyoscine resulted in intermediate values (lower than atropine but higher than controls). Hyoscine and atropine resulted in significantly higher CI than controls for 5 and 20 min, respectively; but this effect coincided with significant hypertension (mean arterial pressures >180 mmHg). Auscultation scores decreased from baseline in all treatments. Time to return to auscultation scores ≥12 (medians) did not differ between hyoscine (4 h) and controls (4 h) but atropine resulted in significantly longer time (10 h). Atropine induced colic in one horse. Gastrointestinal transit times did not differ between treatments. Conclusion: Hyoscine is a shorter acting positive chronotropic agent than atropine, but does not potentiate the impairment in intestinal motility induced by detomidine. Because of severe hypertension, routine use of anticholinergics combined with detomidine is not recommended. Potencial relevance: Hyoscine may represent an alternative to atropine for treating bradycardia.